Brief: Adverum Biotechnologies Announces First Subject Dosed With Ixo-Vec In The Phase 2 Luna Trial For The Treatment Of Wet Age-Related Macular Degeneration
14/09/2022 13:59
Sept 14 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES ANNOUNCES FIRST SUBJECT DOSED WITH
IXO-VEC IN THE PHASE 2 LUNA TRIAL FOR THE TREATMENT OF WET
AGE-RELATED MACULAR DEGENERATION
* ADVERUM BIOTECHNOLOGIES INC - INTERIM DATA ANTICIPATED
THROUGHOUT 2023
* ADVERUM BIOTECHNOLOGIES - PRIMARY ENDPOINTS OF LUNA TRIAL
INCLUDE MEAN CHANGE IN BCVA FROM BASELINE TO 1 YEAR, INCIDENCE &
SEVERITY OF ADVERSE EVENTS
Source text for Eikon: ID:nGNX2Qcgmy
Further company coverage: ADVM.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)